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Although bacteriophage φX174 is easy to propagate and genetically tractable, it is use as a peptide
display platform has not been explored. One region within the φX174 major spike protein G tolerated 13
of 16 assayed insertions, ranging from 10 to 75 amino acids. The recombinant proteins were functional
and incorporated into infectious virions. In the folded protein, the peptides would be icosahedrally
displayed within loops that extend from the protein's β-barrel core. The well-honed genetics of φX174
allowed permissive insertions to be quickly identiﬁed by the cellular phenotypes associated with cloned
gene expression. The cloned genes were easily transferred from plasmids to phage genomes via
recombination rescue. Direct ELISA validated several recombinant virions for epitope display. Some
insertions conferred a temperature-sensitive (ts) protein folding defect, which was suppressed by global
suppressors in protein G, located too far away from the insertion to directly alter peptide display.
Published by Elsevier Inc.Introduction
Inexpensive and quick to propagate, bacteriophages are attrac-
tive platforms for multivalent peptide display (Brown et al., 2002;
Clark and March, 2006; Danner and Belasco, 2001; Ren and Black,
1998; Shivachandra et al., 2007; Smith, 1985; Sternberg and Hoess,
1995; Tumban et al., 2011). Numerous systems based on bacter-
iophages T4, T7, λ, MS2, PP7, Qβ, and ﬁlamentous phage have been
developed for diverse applications, which include the selection of
peptide or protein binders through phage display, the development
of novel imaging reagents, biosensors, bio-nanoconjugate applica-
tions, and for antigen display platforms for serological assays, epi-
tope mapping, and vaccine development (Henry et al., 2015; Lee et
al., 2013; Levy et al., 2007; O'Rourke et al., 2015; Seker and Demir,
2011). Peptide display from viral capsid or virus-like particle (VLP)
scaffolds is empirical by nature; it is impossible to predict whether a
given peptide will be tolerated or will perform successfully in anymunobiology, The University
ane),given application. Although many systems have been described, no
one platform is perfect for the display of every peptide and every
technology. Differences in peptide valency, arrangement, geometry,
and conformation of display may have profound and unanticipated
differences in performance (Jagu et al., 2015; Krause et al., 2006;
Wu et al., 2015). Finally, for vaccine applications, display of a par-
ticular peptide antigen on multiple VLP display platforms may be
necessary to avoid unwanted immunity towards the carrier after
multiple immunizations (Jegerlehner et al., 2010). Further explora-
tion of novel peptide display platforms is therefore warranted.
Here, we sought to expand the phage-based peptide display
options by investigating the utility of bacteriophage φX174, a very
genetically tractable system (Chen et al., 2007; Cherwa et al.,
2009). Although φX174 structure, assembly, genetics, and repli-
cation have been extensively studied, this well-characterized sys-
tem has never been explored as a peptide-display platform. φX174
is the canonical microvirus species within the Microviridae.
Although the (þ) single-stranded DNA genomes are small (5.4–
6.1 kilobases), the use of overlapping reading frames allow them to
encode as many as 12 genes (Doore et al., 2014). The genes
encoding the scaffolding, DNA replication, and lysis functions can
K.J. Christakos et al. / Virology 488 (2016) 242–248 243overlap extensively, whereas the structural proteins are encoded
in regions dedicated to four single genes.
Virions display T¼1 icosahedral symmetry. Along with the
circular genome, the capsid’s interior contains 60 copies of the
DNA binding protein J and 10–12 copies of the DNA pilot protein H,
which emerges from the capsid as a tube on the cell surface (Sun
et al., 2014). The exterior is composed of 60 copies each of the viral
coat F and major spike G proteins. Both proteins consist of eight
anti-parallel β-strands arranged into a classical β-barrel motif
(McKenna et al., 1994). Nascent spike proteins quickly fold and
accumulate as soluble pentamers inside infected cells before being
assembled into soluble sub-virion capsomeres (Cherwa et al.,
2008). Unlike the viral coat protein, which forms extensive pro-
tein–protein interactions with both the external and internal
scaffolding proteins throughout morphogenesis, the upper and
side surfaces of G protein pentamers are solvent exposed, forming
the 12 prominent spikes that decorate the icosahedral 5-fold axes
of symmetry in both virion and procapsid X-ray structures
(Dokland et al., 1999, 1997; McKenna et al., 1994). Thus, protein G
appeared to be the most suitable for peptide display. In this study,
we identiﬁed an exposed surface loop in the major spike proteinFig. 1. Structure of bacteriophage φX174. (A) Isosurface tracing of the φX174 atomic struc
The location of foreign antigen display at Thr21 is highlighted in red. The 5-fold axis of sy
β-strands are depicted in yellow and loops are depicted in blue. The location of the inser
location of the second site suppressors at amino acids Ala83, Thr105, and Ala106 are depi
HA particles: degraded procapsids (70S) and virions (114S) from extracts of infected cell
φX174 infection (upper blot) and a φX-HA infection (lower blot). (E) Side by side comp
depicting proteins F, H, and G, and uninfected cell lysate (C) are shown as well. G spike pr
(see text for details).that could tolerate a wide variety of amino acid insertions ranging
from 10-75 amino acids.Results and discussion
ldentiﬁcation of a φX174G protein insertion loop suitable for peptide
display
Due to the protein's prominent, icosahedrally-ordered surface
display and the lack of scaffolding protein interactions during
assembly (Dokland et al., 1999; McKenna et al., 1994), the major
spike protein was identiﬁed as the optimal protein for peptide
display (Fig. 1A). Codons 20–29 of the HPV16 L2 gene were used as
the model peptide for these initial pilot experiments. This region
encodes a conserved neutralizing epitope: 20KTCKQAGTCP29
(Gambhira et al., 2007; Rubio et al., 2011) that forms a disulﬁde-
bonded loop in the L2 minor capsid protein of mature Human
Papillomavirus Type 16 virions (Campos and Ozbun, 2009).
L2(20-29) encoding DNAs were ﬂanked by BamHI and BspEI linkers
to facilitate cloning. The linker-encoded Gly-Ser and Ser-Glyture. Spike protein G and coat protein F are, respectively, depicted in blue and grey.
mmetry is marked with a pentagon. (B) The atomic structure of the spike protein G.
tion sites after amino acids 21, 47, 151, and 153 are indicated with black arrows. The
cted with red dots. (C) Sedimentation proﬁles of assembled φX174 wild type and φX-
s at 42 °C. (D) SDS-PAGE of small particle (6S-12S) gradient fractions of a wild-type
arison of SDS-PAGE of infected cell lysates and 6S fractions. Procapsid marker (P),
otein bands and the host cell normalization protein band are indicated with arrows
Table 1
Complementation and recombination viability of am(G)Q33 with amino acid insertion clones.
Plasmid characteristics Recombinant phage characteristics
Cell line Cell viabilitya Complementation of am(G)Q33 b Recombination rescue Name and phenotype Suppressors
BAF5(supE)b NAc 1.0 NA NA NA
C122 (sup)b NA o5106 NA NA NA
BAF30 with
pφXG 7 0.8 NA NA NA
pφXG21-L2(20-29)  NA 5105 φX-L2, weak tsd A83De,V and T
T105A, A106D
pφXG47-L2(20-29) þ o5.0106 o2.0107 NA NA
pφXG151-L2(20-29) þ o5.0106 o2.0107 NA NA
pφXG153-L2(20-29) þ o1103 o2.0107 NA NA
pφXG21-HA 7 1.0 5.0105 φX-HA, ts insert changesf with
A83V or A106D
pφXG21-myc  NA 8.6105 φX-myc NA
pφXG21-BTAG  NA 6.5105 φX-BTAG NA
pφXG21-L2(16-36) þ o8104 o7.8107 NA NA
pφXG21-PSTCD 7 0.3 See text See text NA
pφXG21-M2a  NA 2.1104 φX-M2a NA
pφXG21-M2b  NA 2.0104 φX-M2b, ts A83V
pφXG21-M2c  NA 3.0104 φX-M2c, weak ts A83V
pφXG21-CSa  NA 6.0105 φX-CSa, weak ts A83D
pφXG21-CSc þ NA o5.1106 NA NA
pφXG21-CSd þ NA o3.3106 NA NA
pφXG21-CSe  NA 3.0105 φX-CSe NA
Not applicable.
a Indicates whether induction of the clone gene prevented lawn formation. Symbols: þ , no effect on lawn formation, 7 , a moderate effect, – complete inhibition of cell
growth.
b Assay titer/most permissive titer.
c BAF5 cell line contains a tRNA informational suppressor, inserting glutamine during protein synthesis. C122 does not contain an informational suppressor.
d A weak ts phenotype was deﬁned as a plating efﬁciency between 0.1–1.0 at 42 °C compared to 33 °C and plaques displayed a pin-prick morphology. Phage with other ts
phenotypes yielded 42 °C plating efﬁciencies of 104 or lower. When no phenotype is given the phenotype closely resembled wild-type.
e All suppressors were intragenic. Nomenclature: amino acid substitutions in the protein G: wild-type amino acid, position, substituted amino acid. Thus, A83D, an
alanine to a aspartic acid at residue 83.
f These phages contained mutations within the HA insert as well as in G protein. The changes in the insert were Y5F, Y10H, D9G. Numbering of the insert is the same as
given in Table 2.
Table 2
Amino acid insertions placed at position Thr21 of G protein.
Insert and description Length Charge Sequence Tolerateda
L2(20–29) HPV16 L2 14 þ2 GSKTCKQAGTCPSG Yes
HA epitope tag 13 2 GSYPYDVPDYASG Yes
Selected variant 13 2 GSYPFDVPDYASG Yes
Selected variant 13 1 GSYPYDVPGYASG Yes
Selected variant 13 2 GSYPYDVPDHASG Yes
myc Epitope tag 14 3 GSEQKLISEEDLSG Yes
BTAG Epitope tag 10 0 GSQYPALTSG Yes
L2(16–36) HPV16 L2 25 þ2 GSTQLYKTCKQAGTCPPDIIPKVSG No
PSTCD Biotin ligase substrate 75 2 GSGEGEIPAPLAGTVSKILVKEGDTP Yes
KVSGTVLVLEAMKMETEINAPTDGK
VEKVLVKERDAVQGGQGLIKGGSG
M2a Inﬂuenza A M2 protein 13 2 GSSLLTEVETPSG Yes
M2b Inﬂuenza A M2 protein 15 2 GSHYSLLTEVETPSG Yes
M2c Inﬂuenza A M2 protein 15 1 GSSLLTEVETPTRSG Yes
CSa P. falciparum CS protein 16 0 GSNANPNANPNANPSG Yes
CSc P. falciparum CS protein 24 0 GSNANPNANPNANPNANPNANPSG No
CSd P. falciparum CS protein 28 0 GSNANPNANPNANPNANPNANPNANPSG No
CSe P. falciparum CS protein 28 1 GSNANPNVDPNANPNANPNANPNANPSG Yes
a Indicates whether the insertion was tolerated within the phage genome or yielded a complementing clone. The PTSCD insertion was too large to be moved into the
genome, see text for details.
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tope was inserted into four different locations within a com-
plementing, plasmid-based, φX174 major spike gene (Table 1).
This positively charged 14-mer epitope would theoretically be
displayed after positions Thr21, Leu47, Thr151, or Thr153, in one of
three loops that extend off of the G protein's Swiss jellyroll core
(Fig. 1B, Table 2).Although it is possible to conduct complementation assays with
expression plasmids containing the cloned wild-type φX174G gene,
induction is somewhat toxic to host cells. Modiﬁed gene G induction
conferred two distinct phenotypes, neither of which resembled the
wild-type control (Table 1). The induction of the cloned φXG21-L2
gene killed host cells, whereas φXG47-L2, φXG151-L2 and φXG153-L2
gene induction resulted in no observable toxicity. Unlike the wild-type
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(G)Q33 mutant. The elevated or decreased toxicity levels proved a very
reliable readout for G protein functionality (see below).
To determine if altered genes could be placed directly into
viable phage genomes, recombination rescue experiments were
performed. φX174 am(G)Q33 was plated on plasmid containing
cells without IPTG induction. Two genetic mechanisms will allow
plaque formation; 1) direct reversion of the am phenotype,
yielding wild-type φX174 or 2) recombination with the cloned
gene, yielding a genomic gene with an in-frame insertion. To
distinguish between these alternatives, plaques were screened for
altered phenotypes by stabbing them into host cell lawns incu-
bated overnight at 33 °C and 42 °C. In all instances, it was possible
to distinguish between wild-type and insertion-containing φX174
strains. Wild-type φX174 produced a large clearing surrounded by
a thick halo, whereas the recombinant strains produced small
clearings with sharp edges. This phenotypic correlation was ver-
iﬁed by DNA sequencing, and was observed with other recombi-
nant strains (see below). At position Thr21, viable recombinants
were recovered at a frequency of 5.0105. Recombinants were
not recovered at Leu47, Thr151, or Thr153 (frequencyo107).
These data suggest that only the loop at Thr21 could tolerate the
insertion of the neutralizing L2(20-29) epitope (Table 1).
The identiﬁed φX174G protein insertion loop can tolerate many
inserted peptides
To determine if other insertions were tolerated at Thr21, a
variety of peptide encoding DNAs were cloned as described above
(Tables 1 and 2). We tested a diverse set of model epitope tags and
fusion domains: hemagglutinin (HA) epitope, myc epitope, the
Bluetongue virus VP7 epitope tag (BTAG), and the P. Shermanii
transcarboxylase domain (PSTCD); as well as bona ﬁde neutralizing
epitopes from HPV16 L2 (RG-1), Inﬂuenza A virus M2 protein (M2),
and the circumsporozoite protein (CS) from Plasmodium falciparum
(Gambhira et al., 2007; Murtif et al., 1985; Reddy et al., 2000;
Wang et al., 1996; Young et al., 2012; Zavala et al., 1985; Zebedee
and Lamb, 1988). These inserts encompass a wide variety of sizes,
charges, and side chain chemistries (Table 2).
Cloned genes were assayed for elevated host cell toxicity upon
induction and the ability to complement φX174 am(G)Q33. As can
be seen in Table 1, three phenotypes were associated with the
induced clones: complementing (plating efﬁciencies40.1), non-
complementing (plating efﬁciencieso102) with no associated
host-cell toxicity, or elevated host cell toxicity. Recombination
rescue experiments were performed as described above. In all
cases, recombinant phages were recovered using the com-
plementing and/or toxic genes with small inserts. The modiﬁed
gene with the 75 residue PSTCD domain complemented the φX174
mutant. The insertion would add 228 nucleotides to the viral
genome, which exceeds the stringent 102% limit for genome
encapsidation (Aoyama and Hayashi, 1985). Thus, recombination
rescue experiments were not performed. In total, 13/16 inserts
were tolerated, implying high permissibility for foreign peptide
insertion at Thr21.
Correlation between the toxicity of induced cloned genes and mod-
iﬁed G protein function
Cloned gene induction resulted in three phenotypes vis-à-vis
host cell viability. At 33 °C, cells harboring the wild-type φX174G
gene can tolerate IPTG concentrations of 1.0 mM, which leads to
the efﬁcient complementation of am(G) mutants. 5.0 mM IPTG
concentrations kills cells. When modiﬁed cloned gene induction
resulted in a similar phenotype, complementation and recombi-
nation rescue were also observed. Thus, these modiﬁed G proteinsassume a near wild-type fold. Induced genes that had no effect on
host cell viability neither complemented nor yielded recombinant
phages. If host cell toxicity is a function of the folded protein, these
recombinant proteins are likely unable to fold. Lastly, the induc-
tion of some clones was too toxic for complementation assays. In
all instances, these clones yielded recombinant phages. Although
the exact mechanism conferring elevated toxicity is not known, it
appears to serve as a reliable and convenient measure of whether
an insert will ultimately result in a viable recombinant phage.
Recovered recombinant φX174 particles exhibit varying phenotypes
Some recombinant viruses, φX-HA and φX-L2, exhibited
temperature-sensitive (ts) phenotypes, growing poorly above
37 °C (Table 1). To investigate the nature of this defect, φX-HA
phage generated at 33 °C were assayed for particle stability, host
cell attachment kinetics, and eclipse kinetics at 42 °C. At the
restrictive temperature, φX-HA did not differ signiﬁcantly from
wild-type (data not shown). To investigate possible protein folding
and/or particle assembly defects, lysis resistant cells were infected
with either wild-type φX174 or φX-HA at 42 °C. After a 4-hour
incubation, extracts were prepared and analyzed by rate zonal
sedimentation. Particles, regardless of infectivity, are detected by
UV spectroscopy. The sedimentation proﬁles for complexes with
70-140S values are depicted in Fig. 1C. Mutant virion yields were
dramatically lower than wild-type. However, the speciﬁc infec-
tivity of the φX-HA 114S peak fraction was not reduced: 51011
pfu/A280 vs. 6.01011 pfu/A280, respectively. Moreover, signiﬁcant
amounts of off-pathway, uninfectious particles (70S) were not
detected (Fig. 1C). These data suggest that the ts defect affects
protein folding and/or is manifested during early assembly.
The presence of smaller assembly intermediates was examined
by SDS-PAGE of gradient fractions within the 6S-12S range, which
contain the early assembly intermediates (Fig. 1D). Unlike the
wild-type control, 12S* particles were not detected in φX-HA
infected cell extracts (Fig. 1C). This particle contains the F, G, B
and H proteins in a respective 5:5:5:1 ratio. It is formed by the
addition of one G protein pentamer (6S particle) to the 9S* inter-
mediate. 6S gradient fractions, containing soluble G protein pen-
tamers were compared side by side on an SDS-PAGE gel (Fig. 1E).
The intensity of the G protein band was normalized to a host
protein band, which is present in both cell lysates and 6S fractions
and indicated in Fig. 1E. In whole cell lysates, this protein G:host
protein ratio measures total cellular G protein, regardless of
solubility. Protein G was abundant in both the wild-type and φX-
HA whole cell lysates with ratios of 2.7 and 1.6, respectively. The G
protein levels in the 6S fraction roughly estimates the amount of
folded soluble protein. If mutant 6S particles form but are not
incorporated into 12S* particles, they would accumulate in this
fraction. Within the 6S fraction, the wild-type protein G: host
protein ration is 1.5. By contrast, the φX-HA protein G:host protein
ratio is only 0.2. Thus, φX-HA 6S particles appear to be vastly
underrepresented when compared to the wild-type control. These
data indicate that the HA recombinant G protein folds poorly at
42 °C and is unable to assemble into 6S* pentamers.
Second-site suppressors within G correct for high-temperature
growth defects
Suppressors of the ts phenotype were selected by plating φX-
HA, φX-M2b, φX-M2c, and φX-CSa and φX-L2 at 42 °C, as
described in Materials and Methods. Seven independent phage
preparations were used to isolate suppressors of the φX-L2 ts
growth defect. The A83V mutation was isolated thrice indepen-
dently, whereas the A83D mutation was isolated twice indepen-
dently. Thus, the selection likely approached saturation (Luria and
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Ala106 (Table 1). These substitutions affect two different insertion
loops within the G protein (Fig. 1B). In less exhaustive selections,
substitutions for A83 were isolated in the φX-M2b, φX-M2c, and
φX-CSa backgrounds. The suppressor of the φX-HA ts phenotype
were located directly within the HA insertion (Tables 1 and 2).
However, one of these substitutions HA-D9G was always isolated
in conjunction with either the A83V or A106D mutations. These
results indicate that most folding defects can be corrected by
global suppressors located too far away from the insertion to
directly alter antigen display.
Recombinant φX174 virions display foreign antigens
Antibodies against the HPV16-L2 epitope used in these studies
can neutralize HPV infections in vitro (Gambhira et al., 2007; Rubio
et al., 2011), and elicit protective humoral responses in animal
studies (Alphs et al., 2008; Jagu et al., 2009). To determine if these
previously characterized anti-L2 monoclonal antibodies (mAbs)
recognize their cognate epitope displayed on recombinant φX-L2
particles, enzyme-linked immunosorbent assays (ELISAs) were
performed as described in Materials and methods. We compared
anti-L2 antibody binding to wild-type φX174, recombinant φX-L2,
and free L2(13–36) peptide. The free and displayed peptide con-
centrations were identical. Thus, differences may reﬂect whether a
particular antibody has a preference for free or constrained anti-
gen. To determine whether the global suppressors of G protein
folding defects alter antibody recognition, φX-L2 particles con-
taining the A83V, A83D, and A106D substitutions were also
examined.
As can be seen in Fig. 2, mAbs RG-1, K18L2(20–38), and K4L2(20–38)
efﬁciently and speciﬁcally bound the recombinant φX-L2 particles
in all genetic backgrounds. No signiﬁcant reaction was observedFig. 2. : Antigen display on the surface of recombinant φX174 particles. (A, B, C) Detectio
φX-L2 suppressor mutant particles with (A) RG-1, (B) K18, and (C) K4 anti-L2 monoclona
L2(13–36) peptide, were pre-bound to each well. Direct ELISA comparing wild-type φX174 t
BTAG with anti-BTAG antibody.with wild-type φX174. The mAbs appeared to differ in their pre-
ference for displayed or free L2 epitope. mAb RG-1 bound more
efﬁciently to φX-L2 particles (Fig. 2A), whereas mAb K4 had a
preference for the free peptide (Fig. 2C). By contrast, mAb K18
bound equally well to antigen in either context (Fig. 2B). The pre-
sence of the ts protein suppressors did not appear to signiﬁcantly
affect mAb binding (Fig. 2A–C). Using commercially available anti-
bodies against the HA, myc, and BTAG epitopes, direct ELISA was
performed with the respective φX-HA, φX-myc, and φX-BTAG
recombinant particles. Again, the recombinant antigen-displaying
particles were speciﬁcally recognized, whereas no signiﬁcant reac-
tionwas observed with wild-typeφX174 particles (Fig. 2D–F). These
data suggest a broad utility for φX174G protein antigen display.
In summary, we have explored bacteriophage φX174 as a
peptide display platform and we have identiﬁed Thr21 as a per-
missive site for display from the G protein spikes at the vertices of
φX174. Although several speciﬁc insertions caused a ts defect in G
protein folding, suppressor mutants of the ts phenotype were
readily isolated. In all cases tested, the inserted epitopes were
efﬁciently displayed and readily bound by speciﬁc antibodies. The
apparent plasticity of the Thr21 site, tolerating 13 of 16 insertions,
make φX174 an attractive alternative for a variety of peptide and
antigen display applications. As with other bacteriophages, large
quantities of mature and empty particles (DNA-less) can easily be
generated and puriﬁed, facilitating their use in such applications
(Cherwa et al., 2011; Dokland et al., 1997; Roof et al., 1994).
Interestingly, there is a historical precedent of using infectious
φX174 particles to study antibody responses and immunoglobulin
class switching in animals and humans (Mc Guire et al., 2010; Ochs
et al., 1971, 1986; Peacock et al., 1973; Smith et al., 2014), a salient
feature which may offer commercial and regulatory advantages
should φX174-based vaccine technology be further developed.n of L2 antigen by direct ELISA of free L2(13–36) peptide, wild-type φX174, φX-L2, and
l antibodies. Equimolar amounts of L2 antigen, 100 ng of φX174 particles or 6.26 ng
o (D) φX-HAwith anti-HA antibody, (E) φX-myc with anti-myc antibody, and (F) φX-
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Phage plating, media, buffers, stock preparation, kinetic assays, and
particle synthesis
The reagents, media, buffers, and protocols have been pre-
viously described (Fane and Hayashi, 1991). To assay phage stabi-
lity, 108 plaque-forming units (pfu) were added to 10 ml of pre-
warmed media (1.0% tryptone, 0.5% KCl, 0.01 M MgCl2, 0.005 M
CaCl2). Aliquots were removed at regular time intervals, placed on
ice, and surviving phages quantiﬁed by standard plating assays.
Protocols for attachment and eclipse assays (Cherwa and Fane,
2009), and particle puriﬁcation by rate zonal sedimentation
(Cherwa et al., 2011) have been previously described.
Bacterial strains, phage strains, and plasmids
The wild-type Escherichia coli C strain C122 (sup°), amber sup-
pressing strain BAF5 (supE) and strain BAF30 (recA) have been
previously described (Fane and Hayashi, 1991; Fane et al., 1992).
The host slyD mutation confers resistance to E-protein-mediated
lysis (Roof et al., 1994).
To clone the wild-type G gene with 50 and 30 regulatory regions,
nucleotides 2360-3150 from the φX174 genome were ampliﬁed by
PCR. The upstream primer introduced an Nco I site. The resulting
fragment was digested with Nco I and Hae III. The Hae III site is
located at nucleotide 3128. It was inserted into the IPTG-inducible
bacterial expression plasmid pSE420 (Invitrogen) between the Nco
I and Stu I sites. The plasmids pφXG21-L2(20–29), pφXG47-L2(20–29),
pφXG151-L2(20–29), pφXG153-L2(20–29) were generated by overlap
extension PCR of the G gene, and cloned into pSE420 with Nco I
and Hind III, which is located downstream from the Stu I site. The
L2(20-29) insertion was engineered to have ﬂanking BamHI and
BspEI sites, which encode Gly-Ser and Ser-Gly linkers. Plasmids
pφXG21-myc, pφXG21-HA, pφXG21-L2(16-36), pφXG21-BTAG,
pφXG21-PSTCD, pφXG21-M2a, pφXG21-M2b, pφXG21-M2c,
pφXG21-CSa, pφXG21-CSc, pφXG21-CSd, and pφXG21-CSe were
generated from pφXG21-L2(20-29) by BamHI/BspEI replacement of
the L2(20-29) insert with new inserts generated by either annealed
oligonucleotides or PCR.
Complementation and recombination rescue assays
To assay for recombinant G protein complementation, am(G)
Q33 was plated on a plasmid containing cell line with ampicillin
(25 mg/ml) and isopropyl β-D-1-thiogalactopyranoside (IPTG) at
concentrations between of 0.5–5 mM, and incubated for 4–24 h at
33 °C. IPTG-mediated induction was either toxic to cell viability,
yielded plaques, or did not complement with am(G)Q33. To rescue
viable recombinants, am(G)Q33 was plated on a given cell line
with ampicillin but without IPTG, and incubated for 6 hours at
33 °C. Resulting plaques were stabbed into C122 (sup°) lawns
incubated at 33° and 42°. Putative recombinant phages were
identiﬁed by altered growth patterns and veriﬁed by direct DNA
sequence analyses.
Isolation of second site suppressor of temperature-sensitive
phenotypes
The recombinant strains φX-L2, φX-M2b,φX-M2c, φX-CSa, and
φX-HA served as the starting point for the isolation of second site
suppressors. The second site suppressors were selected for their
ability to suppress high temperature growth defects at 42 °C. Due
to their leaky phenotype, approximately 1000 plaque-forming
units of φX-L2, φX-M2c, and φX-CSa were plated at 42 °C and
incubated for 4 h on the wild-type host C122. The plate contentswere washed with 5.0 ml HFB and wash dilutions were plated.
Large plaques exhibiting reversion of the ts phenotype were
picked and the second site suppressors were identiﬁed by a DNA
sequence analysis. As the ts phenotype of φX-HA and φX-M2b was
tight, second site suppressors were directly selected from utilizing
106–107 pfu.
Phage concentration estimation
Puriﬁed phage sample was compared by SDS-PAGE with pro-
capsid marker and 1.6 μg bovine serum albumen (BSA). Intensities
of the sample coat F protein and BSA bands were analyzed by
densitometry and used to estimate the total phage concentration
of the sample. The viral coat protein and BSA have similar mole-
cular weights.
L2 peptide synthesis
Free L2(13–36) peptide antigen (FITC-Ahx-ASATQLYKTCK-
QAGTCPPDIIPKV-acid) was obtained from Pepscan (Lelystad,
Netherlands) and was synthesized with an N-terminal FITC group
and a C-terminal carboxylic acid group by solid phase Fmoc
chemistry. Peptide was puriﬁed to 95% as determined by analytical
HPLC and validated by LC/MS. Peptide was dissolved in deionized
H2O and stored at 80 °C.
Direct ELISAs
Wild-type φX174, recombinant phages or free L2 peptide were
diluted into PBS buffer (2.67 mM KCl, 1.47 mM KH2PO4, 137.93 mM
NaCl, 8.06 mM Na2HPO4-7H2O, pH 7.4) and distributed into a 96-
well ELISA microtiter plate (Nunc Medisorp). φX174 phages were
bound at 100 ng/well and free L2 peptide was bound at 6.26 ng/
well, which corresponds to an equimolar amount of L2 antigen.
The plate was shaken at 700 rpm, room temperature, for 1 hour to
bind targets to the plate. The plate contents were then removed
and blocking solution (TBST, 3% BSA, 1% goat serum) was applied to
the bound targets by shaking for 30 min. The plate contents were
removed and antibody diluted in TBST was bound by shaking for
1 hour. Mouse anti-L2 antibodies RG-1 (Gambhira et al., 2007), and
K18L220-38 (K18), and K4L220–38 (K4) (Rubio et al., 2011) were
generous gifts from R. Roden and M Müller, respectively. Mouse
anti-HA (Applied Biological Materials #G036), mouse anti-myc
(GenScript #A00704), and rabbit anti-BTAG (GenScript #A00638)
were used. Mouse sera from immunization experiments was
mixed and brieﬂy pelleted at 8,000 g prior to preparation of
serial dilutions in TBST. The plate contents were removed and
washed four times with TBST by shaking for several minutes.
Secondary antibody (goat anti-mouse-HRP conjugate or anti-rab-
bit) diluted in TBST was added. The plate contents were removed
and washed four times with TBST by shaking for several minutes.
TMB substrate (Calbiochem #613544) was added and shaken until
the signal was visually strong (2–10 min). The reaction was stop-
ped with 2.0 M HCl, and the absorbance at 450 nm was measured
with a DTX-800 multimode plate reader (Beckman Coulter).Acknowledgements
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